GRC 39815 / Glenmark - LARVOL DELTA

[VIRTUAL] GRC39815-A novel inhaled ROR?t inhibitor as a potential first in class treatment option for COPD (ERS 2021) - "GRC39815 is a novel, selective and safe inhaled RORγt inverse agonist for potential antiinflammatory treatment of COPD and currently in Phase-1 clinical trial to evaluate safety, tolerability and pharmacokinetics in healthy adults."

Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL17A • IL22

Glenmark Pharmaceuticals Ltd Management Discussion & Analysis for the First Quarter of FY 2021-22 (Glenmark Press Release) - "GRC 39815 (RORγt inhibitor): GRC 39815 (RORγt antagonist) is the company’s respiratory pipeline asset being developed as an inhaled therapy for treatment of mild to moderate COPD. It is currently under Phase 1 clinical development with a single ascending dose study in the US. The Phase 1 study is expected to be completed in the next few quarters."

Trial status • Chronic Obstructive Pulmonary Disease • Respiratory Diseases